Çalışmamızda Eskişehir Osmangazi Üniversitesi İç Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı’nda takip ve tedavisi yapılan, Ocak 2008-Aralık 2018 tarihleri arasında, WHO 2008 Hodgkin lenfoma (HL) tanı kriterlerine göre tanı alan hastaların; demografik, histopatolojik, prognostik özelliklerini belirlemeyi ve bu belirteçlerin sağkalım üzerindeki ilişkisini ortaya koymayı amaçladık. Bu amaçla 130 hasta retrospektif olarak değerlendirildi. Hastaların %61.5’i (n=80) erkekti, yaş ortalaması 46.5±15.8 (20-89) yıldı. Tanı sırasında hastaların %21.6’sı erken evre, %78.6’sı ileri evreydi. En sık tanı evre Ⅱ’de (%34.6) konulmuştu. Hastalardan %93.1’i klasik HL, %6.9’u nodüler lenfosit predominant HL tanısı almıştı, %48.62’sı nodüler sklerozan HL (NSHL), %15.7’si mikst selüler HL, %3.3’ü lenfositten fakir HL ve %7.9’u lenfositten zengin HL tanılıydı. NSHL tüm hastalarda, kadınlarda ve erkeklerde en sık görülen alt gruptu. Çalışmamızda NSHL’nın 20’li ve 40’lı yaşlarda pik yaptığı görüldü. Hastaların tanı anında %67.7’sinde B semptomu mevcuttu ve en sık görülen B semptomu ateş idi. %43.8’inde ekstranodal (EN) tutulum mevcuttu ve en sık dalak tutulumu (%30) olduğu görüldü 1. basamak tedavide hastaların %99.2’si ABVD aldı. Toplam 18 hastada (%13.8) relaps görüldü. Evrelere göre genel sağkalım (OS) ve relapssız sağkalımlara (RFS) bakıldığında evre Ⅰ’de en yüksek, evre Ⅳ’te en düşüktü. Tüm hastalara göre bakıldığında 5 yıllık OS %88.7, 5 yıllık RFS %83.9, 10 yıllık OS %82.2, 10 yıllık RFS %82.4 olarak bulundu. Prognostik faktörlerin değerlendirilmesinde tek değişkenli analizde yaş (p=0.001), EN tutulum (p=0.007), kemik iliği tutulumu (p=0.05), ECOG performans skoru (p<0.001), B semptom varlığı (p=0.049), hemoglobin (p<0.0001), albümin (p<0.0001), alkalen fosfataz (ALP) (p=0.0001) prognostik faktörler olarak bulundu. Çok değişkenli analizde yaş (p<0.001), albümin (p=0.041), ALP (p=0.005), lökosit sayısı (p=0.028) prognostik faktörler olarak saptandı
In our study, the patients who were followed up and treated in Eskişehir Osmangazi University Department of Internal Diseases, Department of Hematology, and diagnosed according to WHO 2008 Hodgkin lymphoma (HL) diagnostic criteria between January 2008 and December 2018; We aimed to determine the demographic, histopathological and prognostic features and to reveal the relationship of these markers on survival. For this purpose, 130 patients were evaluated retrospectively. 61.5% (n = 80) of the patients were male, the mean age was 46.5 ± 15.8 (20-89) years. At the time of diagnosis, 21.6% of the patients were early stage and 78.6% were advanced. The most common diagnosis was made in stage Ⅱ (34.6%). Of the patients, 93.1% were diagnosed with classical HL, 6.9% were diagnosed with nodular lymphocyte predominant HL, 48.62% were nodular sclerosing HL (NSHL), 15.7% mixed cellular HL, 3.3% lymphocyte poor HL and 7.9% it was lymphocytic HLA diagnostics. NSHL was the most common subgroup in all patients, women and men. In our study, it was observed that NSHL peaked in the 20s and 40s. 67.7% of the patients had B symptom at the time of diagnosis and the most common B symptom was fever. 43.8% had extranodal (EN) involvement and the most common (30%) was found to be splenic involvement. 99.2% of the patients received ABVD in the first line treatment. Relapse occurred in 18 patients (13.8%). Looking at overall survival (OS) and relapse-free survival (RFS) by stages, it was the highest in stage Ⅰ and the lowest in stage Ⅳ. Considering all patients, 5-year OS was 88.7%, 5-year RFS was 83.9%, 10-year OS was 82.2%, 10-year RFS was 82.4%. In univariate analysis in the evaluation of prognostic factor age (p = 0.001), EN involvement (p = 0.007), bone marrow involvement (p = 0.05), ECOG performance score (p <0.001), presence of B symptoms (p = 0.049), hemoglobin (p <0.0001), albumin (p <0.0001), alkaline phosphatase (ALP) (p = 0.0001) were found as prognostic factors. In multivariate analysis, age (p <0.001), albumin (p = 0.041), ALP (p = 0.005), leukocyte count (p = 0.028) were determined as prognostic factors
